We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Mark Soloway

Mark S Soloway MD

Professor and Chair Emeritus of Urology, University of Miami Miller School of Medicine, Miami, Florida

Mark Soloway has devoted himself to the subspecialty of urologic oncology for the past 40 years. He has made significant contributions to the understanding and treatment of the three most common GU cancers – prostate, bladder, and kidney.

During his NCI/NIH fellowship he developed an animal model for bladder cancer (BC) which closely resembles its human counterpart and is still being used. Using these primary and transplantable (MBT 2) murine tumors he identified the then experimental drug cisplatin as an active agent for BC. This led to successful clinical trials at MSKCC.

As a young faculty member at The University of Tennessee Dr Soloway gave systemic cisplatin chemotherapy to his patients with locally advanced and metastatic BC and seeing the benefits suggested a role for induction or neoadjuvant chemotherapy before cystectomy.

He also demonstrated the synergy between cisplatin and radiation for BC. Once again clinical trials proved the benefit of this approach and it remains a standard for bladder preservation for MIBC.

During his residency at University Hospitals of Cleveland Dr. Soloway’s lab proved that altering the urothelium of the murine bladder allowed tumor cells to implant on the bladder surface and suggested that this is one cause for the high recurrence rate following a TUR BT. He advocated for the use of intravesical chemotherapy following a TUR BT. It is now a standard approach to reduce recurrences.

Dr. Soloway was one of the first to highlight the problem of urothelial carcinoma in the prostate in patients with BC and suggested a staging system which had implications for prognosis and treatment.

Dr. Soloway was one of the first to describe and popularize the periprostatic nerve block before a TRUS guided prostate biopsy procedure now performed over 1 million times annually in the US.

He has co authored numerous articles describing and detailing the implications of a positive margin after RP. He has been a proponent for bladder neck preservation during a RP.

Working closely with Gaetano Ciancio they have detailed the merits of using liver transplant techniques to reduce the mortality and morbidity of surgery for large renal and adrenal tumors particularly those with an IVC tumor thrombus.

Dr. Soloway received the Gold Cystoscope Award from the AUA in 1984. He was presented with a Presidential Citation from the AUA in 2000 in part for his emphasis on the case presentation method to enhance the interactive aspect of urology meetings.

Dr. Soloway chaired the SIU and ICUD BC recommendations in 2004 and 2011. He has authored over 500 articles in peer reviewed journals.

Recent Contributions to PracticeUpdate:

  1. VTE in Patients Undergoing Radical Cystectomy for Malignancy